Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP (A-CHOP-14)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2012 by University of Göttingen.
Recruitment status was:  Recruiting
German High-Grade Non-Hodgkin's Lymphoma Study Group
Nordic Lymphoma Group
Information provided by (Responsible Party):
Prof. Dr. Lorenz Trümper, University of Göttingen Identifier:
First received: July 25, 2008
Last updated: May 4, 2012
Last verified: May 2012
Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is significantly worse than that of aggressive B cell lymphomas. The prospects of elderly patients are especially poor, with an estimated disease free survival of only 25% after three years. Previous phase II trials have demonstrated a significant activity of the monoclonal anti CD52 antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients with previously untreated peripheral T cell lymphoma.

Condition Intervention Phase
Peripheral T Cell Lymphoma, Unspecified
Angioimmunoblastic Lymphadenopathy
Extranodal NK/T-cell Lymphoma
Biological: alemtuzumab
Drug: chemotherapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly

Resource links provided by NLM:

Further study details as provided by University of Göttingen:

Primary Outcome Measures:
  • Event free survival [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Rate of complete and partial remissions [ Time Frame: 4 months after inclusion ]
  • treatment related deaths [ Time Frame: time of occurence ]
  • Overall survival [ Time Frame: @ 3 years ]
  • protocol adherence [ Time Frame: 4 months of treatment ]
  • immune reconstitution after alemtuzumab CHOP [ Time Frame: 3 years ]

Estimated Enrollment: 274
Study Start Date: February 2008
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm A
Chemotherapy with dose dense CHOP-14, 6 cycles
Drug: chemotherapy
dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
Other Name: chemotherapy cylcophosphamide, hydroxyldaunorubicin
Experimental: Arm B
Chemotherapy with dose dense CHOP-14, 6-cycles, together with 30mg Alemtuzumab s.c. for the first 4 cycles
Biological: alemtuzumab
Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
Other Name: monoclonal anti CD52 antibody
Drug: chemotherapy
dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
Other Name: chemotherapy cylcophosphamide, hydroxyldaunorubicin


Ages Eligible for Study:   61 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • all risk groups of peripheral T cell lymphoma
  • performance status ECOG 0-2
  • written consent
  • measurable disease

Exclusion Criteria:

  • stage I N without bulky disease
  • already initiated treatment
  • serious accompanying disorder or impaired organ function
  • bone marrow involvement >25%
  • HIV positivity
  • leukemic manifestation of lymphoma
  • simultaneous participation in another trial
  • platelets < 100 000/ mm, leukocytes < 2500 /mm
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00725231

Contact: Lorenz H Trümper, MD +49 551 398535 ext 8535
Contact: Gerald G Wulf, MD +49 551 396303 ext 6303

University of Göttingen Recruiting
Göttingen, Lower Saxony, Germany, 37099
Sponsors and Collaborators
University of Göttingen
German High-Grade Non-Hodgkin's Lymphoma Study Group
Nordic Lymphoma Group
Principal Investigator: Lorenz H Trümper, MD University of Göttingen
  More Information

Additional Information:
Responsible Party: Prof. Dr. Lorenz Trümper, Head of Departement of Haemtology and Oncology, University of Göttingen Identifier: NCT00725231     History of Changes
Other Study ID Numbers: DSHNHL 2006-1B / ACT-2
BMBF GFVT 01014715
Study First Received: July 25, 2008
Last Updated: May 4, 2012

Keywords provided by University of Göttingen:
T cell lymphoma

Additional relevant MeSH terms:
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Lymphoma, Extranodal NK-T-Cell
Immunoblastic Lymphadenopathy
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents processed this record on May 23, 2017